Post-Merger company, Niki BioSolutions, Inc., to Trade on Nasdaq Under Ticker “NIKI”

Aptorum Group Announces 1-for-10 Reverse Share Split and Delaware Redomestication in Connection with the Merger

The Merger is Expected to Close in July 2026

NEW YORK, NY, July 16, 2026 (GLOBE NEWSWIRE) — Aptorum Group Limited, a Cayman Islands exempted company with limited liability (NASDAQ: APM) (“Aptorum Group” or “Aptorum” or “Company”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that the closing of its merger with DiamiR Biosciences Corp. (“Merger”) is anticipated to take place on or about July 20, 2026. DiamiR Biosciences Corp. is a developer and provider of innovative blood-based tests offered through its CLIA-certified, CAP-accredited laboratory for brain health and other conditions.